Cardiff Oncology(US:CRDF) Globenewswireยท2025-10-02 20:05Core Insights - Cardiff Oncology, Inc. is participating in two investor conferences in October 2025, showcasing its focus on PLK1 inhibition for cancer therapies [1][2][3] Group 1: Upcoming Events - Cardiff Oncology will present at the Piper Sandler Virtual Oncology Symposium on October 9, 2025, at 1:00 PM ET, featuring CEO Mark Erlander, CFO James Levine, and CMO Roger Sidhu [2] - The company will also present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference on the same day at 2:00 PM ET, with CEO Mark Erlander as the presenter [3] - Registration for the Noble Capital Markets conference is free, and a webcast replay will be available within 48 hours post-presentation on the company's website [3] Group 2: Company Overview - Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition, targeting various cancers [4] - The lead asset, onvansertib, is being evaluated in combination with standard of care treatments for RAS-mutated metastatic colorectal cancer and other cancers, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer [4] - The company's development strategy aims to exploit tumor vulnerabilities to overcome treatment resistance and provide superior clinical benefits compared to standard therapies [4]